{"id":45457,"date":"2025-10-31T21:03:51","date_gmt":"2025-10-31T13:03:51","guid":{"rendered":"https:\/\/flcube.com\/?p=45457"},"modified":"2025-10-31T21:06:45","modified_gmt":"2025-10-31T13:06:45","slug":"transcenta-holding-announces-positive-phase-iii-results-for-inhibrxs-ozekibart-in-advanced-chondrosarcoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45457","title":{"rendered":"Transcenta Holding Announces Positive Phase\u202fIII Results for Inhibrx\u2019s Ozekibart in Advanced Chondrosarcoma"},"content":{"rendered":"\n

Transcenta Holding Limited (HKG: 6628<\/a>)<\/strong> announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX<\/a>)<\/strong> has reported favorable topline data from the ChonDRAgon<\/strong> phase\u202fIII registrational study (n\u202f=\u202f206) of ozekibart (INBRX\u2011109)<\/strong> versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.<\/p>\n\n\n\n

Based on these outcomes, Inhibrx intends to file for U.S. regulatory approval by the end of June\u202f2026<\/strong>.<\/p>\n\n\n\n

Study and Therapeutic Highlights<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Drug<\/strong><\/td>Ozekibart (INBRX\u2011109) \u2013 a precision\u2011engineered, tetravalent death receptor\u202f5 (DR5) agonist antibody<\/td><\/tr>
Mechanism<\/strong><\/td>Engages tumor\u2011biased apoptosis via DR5 activation<\/td><\/tr>
Trial<\/strong><\/td>ChonDRAgon \u2013 randomized, placebo\u2011controlled Phase\u202fIII (206 patients)<\/td><\/tr>
Endpoints<\/strong><\/td>Not yet disclosed; topline data indicate statistically significant benefit<\/td><\/tr>
Regulatory Status<\/strong><\/td>Fast Track<\/em> (FDA, Jan\u202f2021) & Orphan Drug<\/em> (FDA, Nov\u202f2021) designations for metastatic\/unresectable conventional chondrosarcoma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Licensing and Commercial Rights<\/h3>\n\n\n\n

Transcenta holds exclusive rights<\/strong> to develop and commercialize ozekibart in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan<\/strong> under a license agreement with HJB (Hangzhou) Co., Ltd<\/strong>, a wholly\u2011owned subsidiary of Transcenta. The partnership leverages Transcenta\u2019s regional pipeline expertise and Inhibrx\u2019s late\u2011stage development capabilities.<\/p>\n\n\n\n

Market Implications<\/h3>\n\n\n\n